{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:58:29Z","timestamp":1769201909517,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020274","name":"EUSA Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The evaluation of clinical evidence takes account of health benefit (efficacy and safety) and the degree of certainty in the estimate of benefit. In orphan indications practical and ethical challenges in conducting clinical trials, particularly in paediatric patients, often limit the available evidence, rendering structured evaluation challenging. While acknowledging the paucity of evidence, regulators and reimbursement authorities compare the efficacy and safety of alternative treatments for a given indication, often in the context of the benefits of other treatments for similar or different conditions. This study explores the feasibility of using the Institute for Clinical and Economic Review (ICER) Evidence Rating Matrix for Comparative Clinical Effectiveness in structured assessment of both the magnitude of clinical benefit (net health benefit, NHB) and the certainty of the effect estimate in a sample of orphan therapies for paediatric indications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eleven systemic therapies with European Medicines Agency (EMA) orphan medicinal product designation, licensed for 16 paediatric indications between January 2017 and March 2020 were identified using OrphaNet and EMA databases and were selected for evaluation with the ICER Evidence Rating Matrix: burosumab; cannabidiol; cerliponase alfa; chenodeoxycholic acid (CDCA); dinutuximab beta; glibenclamide; metreleptin; nusinersen; tisagenlecleucel; velmanase alfa; and vestronidase alfa. EMA European Public Assessment Reports, PubMed, EMBASE, the Cochrane Library, Clinical Key, and conference presentations from January 2016 to April 2021 were searched for evidence on efficacy and safety. Two of the identified therapies were graded as \u201csubstantial\u201d NHB: dinutuximab beta (neuroblastoma maintenance) and nusinersen (Type I SMA), and one as \u201ccomparable\u201d NHB (CDCA). The NHB grade of the remaining therapies fell between \u201ccomparable\u201d and \u201csubstantial\u201d. No therapies were graded as having negative NHB. The certainty of the estimate ranged from \u201chigh\u201d (dinutuximab beta in neuroblastoma maintenance) to \u201clow\u201d (CDCA, metreleptin and vestronidase alfa). The certainty of the other therapies was graded between \u201clow\u201d and \u201chigh\u201d. The ICER Evidence Rating Matrix overall rating \u201cA\u201d (the highest) was given to two therapies, \u201cB+\u201d to 6 therapies, \u201cC+\u201d to five therapies, and \u201cI\u201d (the lowest) to three therapies. The scores varied between rating authors with mean agreement over all indications of 71.9% for NHB, 56.3% for certainty and 68.8% for the overall rating.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using the ICER Matrix to grade orphan therapies according to their treatment benefit and certainty is feasible. However, the assessment involves subjective judgements based on heterogenous evidence. Tools such as the ICER Matrix might aid decision makers to evaluate treatment benefit and its certainty when comparing therapies across indications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02701-w","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:12:48Z","timestamp":1689862368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9932-8214","authenticated-orcid":false,"given":"Jaro","family":"Wex","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Szkultecka-Debek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-2386","authenticated-orcid":false,"given":"Mariola","family":"Drozd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Zibelnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"4","key":"2701_CR1","first-page":"213","volume":"31","author":"E Schlegl","year":"2017","unstructured":"Schlegl E, Ducournau P, Ruof J. Different weights of the evidence-based medicine triad in regulatory, health technology assessment, and clinical decision making. Pharmaceut Med. 2017;31(4):213\u20136.","journal-title":"Pharmaceut Med"},{"issue":"7650","key":"2701_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"2701_CR3","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. GRADE Handbook. GRADE. 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed Dec 2020."},{"key":"2701_CR4","unstructured":"Ollendorf DA, Pearson SD. ICER Evidence Rating Matrix: a user\u2019s guide. Institute for Clinical and Economic Review. 2020. Accessed April 2021."},{"issue":"10","key":"2701_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","volume":"28","author":"NI Cherny","year":"2017","unstructured":"Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340\u201366.","journal-title":"Ann Oncol"},{"key":"2701_CR6","unstructured":"de Vries E, Cherny N, Latino N. The ESMO-Magnitude of Clinical Benefit Scale V1.1: user instructions and ESMO-MCBS case studies. Oncology\/pro. https:\/\/oncologypro.esmo.org\/content\/download\/124996\/2367014\/1\/Tips-Tricks-ESMO-MCBS-Detailed-Use-Guidelines-Case-Studies.pdf. Accessed 16 Sept 2022."},{"issue":"3","key":"2701_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494\u2013506.","journal-title":"JBI Evid Synth"},{"issue":"6","key":"2701_CR8","doi-asserted-by":"publisher","first-page":"e027445","DOI":"10.1136\/bmjopen-2018-027445","volume":"9","author":"BS Alper","year":"2019","unstructured":"Alper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, et al. Defining certainty of net benefit: a GRADE concept paper. BMJ Open. 2019;9(6):e027445.","journal-title":"BMJ Open"},{"issue":"4","key":"2701_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315.","journal-title":"Control Clin Trials"},{"issue":"1","key":"2701_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13023-018-0926-z","volume":"13","author":"C Pontes","year":"2018","unstructured":"Pontes C, Fontanet JM, Vives R, Sancho A, Gomez-Valent M, Rios J, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet J Rare Dis. 2018;13(1):206.","journal-title":"Orphanet J Rare Dis"},{"key":"2701_CR11","unstructured":"U.S. Food & Drug Administration. Demonstrating substantial evidence of effectiveness for human drug and biological products: Draft guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products. Accessed Dec 2020."},{"key":"2701_CR12","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Trials in Small Populations. European Medicines Agency. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-trials-small-populations_en.pdf. Accessed Dec 2020"},{"issue":"3","key":"2701_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019;24(3):867\u201372.","journal-title":"Drug Discov Today"},{"issue":"5","key":"2701_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","volume":"21","author":"S Nestler-Parr","year":"2018","unstructured":"Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2018;21(5):493\u2013500.","journal-title":"Value Health"},{"issue":"7","key":"2701_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jval.2017.03.005","volume":"20","author":"E Nicod","year":"2017","unstructured":"Nicod E, Berg Brigham K, Durand-Zaleski I, Kanavos P. Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs: evidence from four European countries. Value Health. 2017;20(7):919\u201326.","journal-title":"Value Health"},{"issue":"6","key":"2701_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/1740774520944855","volume":"17","author":"A Hatswell","year":"2020","unstructured":"Hatswell A, Freemantle N, Baio G, Lesaffre E, van Rosmalen J. Summarising salient information on historical controls: a structured assessment of validity and comparability across studies. Clin Trials. 2020;17(6):607\u201316.","journal-title":"Clin Trials"},{"issue":"2","key":"2701_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1835","volume":"108","author":"RA Vreman","year":"2020","unstructured":"Vreman RA, Naci H, Goettsch WG, Mantel-Teeuwisse AK, Schneeweiss SG, Leufkens HGM, et al. Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clin Pharmacol Ther. 2020;108(2):350\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2701_CR18","first-page":"83","volume":"1","author":"D Tordrup","year":"2014","unstructured":"Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in health technology assessment in eight European countries. Rare Dis Orphan Drugs. 2014;1(3):83\u201397.","journal-title":"Rare Dis Orphan Drugs"},{"issue":"1","key":"2701_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","volume":"12","author":"L Annemans","year":"2017","unstructured":"Annemans L, Aym\u00e9 S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2701_CR20","first-page":"793","volume":"25","author":"LP Garrison","year":"2019","unstructured":"Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"2701_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","volume":"21","author":"LP Garrison","year":"2018","unstructured":"Garrison LP, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, et al. A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]. Value Health. 2018;21(2):161\u20135.","journal-title":"Value Health"},{"issue":"1","key":"2701_CR22","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232100177X","volume":"38","author":"RA Vreman","year":"2022","unstructured":"Vreman RA, Strigkos G, Leufkens HGM, Schunemann HJ, Mantel-Teeuwisse AK, Goettsch WG. Addressing uncertainty in relative effectiveness assessments by HTA organizations. Int J Technol Assess Health Care. 2022;38(1): e17.","journal-title":"Int J Technol Assess Health Care"},{"key":"2701_CR23","unstructured":"Orphanet. Lists of medicinal products for rare diseases in Europe. Orphanet. 2020. https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/list_of_orphan_drugs_in_europe.pdf. Accessed April 2021."},{"key":"2701_CR24","unstructured":"European Medicines Agency. Medicines: orphan designations. European Medicines Agency. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/ema_group_types\/ema_orphan. Accessed April 2021."},{"key":"2701_CR25","unstructured":"European Society for Medical Oncology. ESMO-magnitude of clinical benefit scale v1.1. Evaluation form 3. European Society for Medical Oncology. 2017. https:\/\/www.esmo.org\/content\/download\/117393\/2059180\/1\/ESMO-MCBS-Version-1-1-Evaluation-Form-3.pdf. Accessed April 2021."},{"key":"2701_CR26","unstructured":"European Society for Medical Oncology. ESMO-magnitude of clinical benefit scale v1.1. Evaluation form 1. European Society for Medical Oncology. 2017. https:\/\/www.esmo.org\/content\/download\/117385\/2059134\/1\/ESMO-MCBS-Version-1-1-Evaluation-Form-1.pdf. Accessed April 2021."},{"issue":"3","key":"2701_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jep.13657","volume":"28","author":"B Djulbegovic","year":"2022","unstructured":"Djulbegovic B, Ahmed MM, Hozo I, Koletsi D, Hemkens L, Price A, et al. High quality (certainty) evidence changes less often than low-quality evidence, but the magnitude of effect size does not systematically differ between studies with low versus high-quality evidence. J Eval Clin Pract. 2022;28(3):353\u201362.","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"2701_CR28","doi-asserted-by":"publisher","first-page":"e011666","DOI":"10.1136\/bmjopen-2016-011666","volume":"6","author":"AJ Hatswell","year":"2016","unstructured":"Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999\u20132014. BMJ Open. 2016;6(6):e011666.","journal-title":"BMJ Open"},{"issue":"1","key":"2701_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13023-020-01462-0","volume":"15","author":"E Nicod","year":"2020","unstructured":"Nicod E, Whittal A, Drummond M, Facey K. Are supplemental appraisal\/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis. 2020;15(1):189.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2701_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.publhealth.21.1.587","volume":"21","author":"PJ Neumann","year":"2000","unstructured":"Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21(1):587\u2013611.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"2701_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13023-022-02283-z","volume":"17","author":"MJ Postma","year":"2022","unstructured":"Postma MJ, Noone D, Rozenbaum MH, Carter JA, Botteman MF, Fenwick E, et al. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet J Rare Dis. 2022;17(1):157.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2701_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","volume":"21","author":"DA Ollendorf","year":"2018","unstructured":"Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health. 2018;21(5):547\u201352.","journal-title":"Value Health"},{"key":"2701_CR33","doi-asserted-by":"crossref","unstructured":"Peasgood T, Mukuria C, Rowen D, Tsuchiya A, Wailoo A. Should we consider including a value for \u201chope\u201d as an additional benefit within health technology assessment? Value Health. 2022.","DOI":"10.1016\/j.jval.2022.03.006"},{"issue":"7","key":"2701_CR34","doi-asserted-by":"publisher","first-page":"S505","DOI":"10.1016\/j.jval.2022.04.1142","volume":"25","author":"N Fluetsch","year":"2022","unstructured":"Fluetsch N, Agboola FO, Pearson SD, Campbell J. HTA8 The relationship between ICER\u2019s Evidence Rating Matrix and incremental quality-adjusted life years. Value Health. 2022;25(7):S505.","journal-title":"Value Health"},{"issue":"1","key":"2701_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-020-01370-3","volume":"15","author":"L Annemans","year":"2020","unstructured":"Annemans L, Makady A. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases. Orphanet J Rare Dis. 2020;15(1):127.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2701_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13023-021-01938-7","volume":"16","author":"SE Grimm","year":"2021","unstructured":"Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, et al. Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to \u201cTRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases\u201d). Orphanet J Rare Dis. 2021;16(1):320.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2701_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jep.12993","volume":"24","author":"M Mercuri","year":"2018","unstructured":"Mercuri M, Baigrie BS. What confidence should we have in GRADE? J Eval Clin Pract. 2018;24(5):1240\u20136.","journal-title":"J Eval Clin Pract"},{"issue":"4","key":"2701_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2701_CR39","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/jep.12857","volume":"24","author":"M Mercuri","year":"2018","unstructured":"Mercuri M, Baigrie B, Upshur REG. Going from evidence to recommendations: Can GRADE get us there? J Eval Clin Pract. 2018;24(5):1232\u20139.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"2701_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1378\/chest.129.1.174","volume":"129","author":"G Guyatt","year":"2006","unstructured":"Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174\u201381.","journal-title":"Chest"},{"key":"2701_CR41","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Qarziba (EMEA\/H\/C\/003918\/0000). European Medicines Agency. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qarziba. Accessed Dec 2020."},{"key":"2701_CR42","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Epidyolex (EMEA\/H\/C\/004675\/0000). European Medicines Agency. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex. Accessed Dec. 2020."},{"key":"2701_CR43","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Spinraza (EMEA\/H\/C\/004312\/0000). European Medicines Agency. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed Dec 2020."},{"key":"2701_CR44","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Kymriah (EMEA\/H\/C\/004090\/0000). European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah. Accessed Dec 2020."},{"issue":"3","key":"2701_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","volume":"51","author":"J Bogaerts","year":"2015","unstructured":"Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015;51(3):271\u201381.","journal-title":"Eur J Cancer"},{"key":"2701_CR46","unstructured":"Institute for Clinical and Economic Review. Adapted value assessment methods for high-impact \u201csingle and short-term therapies\u201d (SSTs). Institute for Clinical and Economic Review. 2019. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SST_FinalAdaptations_111219.pdf. Accessed April 2021."},{"issue":"8","key":"2701_CR47","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","volume":"22","author":"A Kordecka","year":"2019","unstructured":"Kordecka A, Walkiewicz-\u017barek E, \u0141apa J, Sadowska E, Kordecki M. Selection of endpoints in clinical trials: trends in European marketing authorization practice in oncological indications. Value Health. 2019;22(8):884\u201390.","journal-title":"Value Health"},{"key":"2701_CR48","unstructured":"Institute for Clinical and Economic Review. Modifications to the ICER value assessment framework for treatments for ultra\u2010rare diseases. Final version. Institute for Clinical and Economic Review. 2017. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER-Adaptations-of-Value-Framework-for-Rare-Diseases.pdf. Accessed April 2021."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02701-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:22:14Z","timestamp":1689862934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02701-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02701-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JW is currently employed, and MSD and NZ were employed, by EUSA Pharma, which markets dinutuximab beta, at the time when the research was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}